SEC Comment Letter for NRX Pharmaceuticals, (NRXP) — Jun 13, 2022
NRX Pharmaceuticals, Inc.
Date: June 13, 2022 · CIK: 0001719406 · Accession: 0000000000-22-006418
AI Filing Summary & Sentiment
File numbers found in text: 333-265492
Letter
United States securities and exchange commission logo June 13, 2022 Alessandra Daigneault, Esq. Chief Corporate Officer, General Counsel & Secretary NRX Pharmaceuticals, Inc. 1201 Orange Street, Suite 600 Wilmington, DE 19801 Re:NRX Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 9, 2022 File No. 333-265492 Dear Ms. Daigneault: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Huntington, Esq.
Show Raw Text
United States securities and exchange commission logo
June 13, 2022
Alessandra Daigneault, Esq.
Chief Corporate Officer, General Counsel & Secretary
NRX Pharmaceuticals, Inc.
1201 Orange Street, Suite 600
Wilmington, DE 19801
Re:NRX Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 9, 2022
File No. 333-265492
Dear Ms. Daigneault:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David Huntington, Esq.